Scoping clinical trial support services: which functions genuinely benefit from being outsourced, how to keep oversight of work you did not do, and the contract terms that decide whether the data and the relationships come back to you at the end

Trial support covers a wide range of functions that are bought together and behave differently: monitoring, data management, central laboratory work, drug supply, statistics and medical writing. Outsourcing transfers the work and never the responsibility, which is the sentence most sponsors learn late. This page covers what to outsource, how to keep oversight and what to fix in the contract.

the regulation under which sponsor responsibility does not transfer
Part 312
the electronic records rule every system in the study must meet
Part 11
the deliverable a sponsor owes whoever performs the work
oversight plan

Figures in this panel are the regulations governing sponsor responsibility and study records, named from the regulations themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a service price index it has not measured.

Scoping and overseeing the work

  1. Separate the functions before pricing them. Monitoring, data management, central laboratory, drug supply, statistics and medical writing have different markets and different specialists. Bundling them with one provider buys convenience; separating them buys the best of each and costs coordination effort.
  2. Keep oversight, because the obligation stays with the sponsor. Regulatory responsibility for trial conduct remains with the sponsor whoever performs the work, so the oversight plan is a deliverable in its own right: what you review, how often, and what triggers escalation.
  3. See the data as the study runs, in an analysable form. Agree interim transfers at defined intervals in a format you can actually analyse. A sponsor seeing its own data monthly finds design and site problems while they are still fixable; one waiting for the final transfer finds them afterwards.
  4. Name the people, not just the company. The project manager, the lead monitor and the data manager determine how the study goes. Name them in the contract, agree notice on replacement, and meet them before signing.
  5. Settle data, documents and site relationships at the end. What is returned at close-out, in what format, who holds the trial master file, how long records are retained and whether you may approach the sites directly afterwards. These are contract terms and they are difficult to add later.

Choosing a provider at your size

A large provider brings process, global reach and a long queue in which a small study is a small study. A specialist brings attention and less depth when something unusual happens. Ask for a reference sponsor of your size in your therapeutic area and ask them how it actually went.

Ask who would be assigned and how many other studies they carry. The answer to that question predicts the experience better than any capability presentation.

Managing the relationship once it is running

Agree a single escalation path and one named decision maker on each side. Studies delayed by a question nobody was empowered to answer are common and entirely avoidable.

Review metrics that mean something: enrolment against plan, query ageing, protocol deviations and monitoring visit completion. A status deck without those is a narrative rather than a report.

Budget and change orders

Change orders are where outsourced study budgets move, and they follow from protocol amendments and from assumptions in the original bid that did not hold. Ask what the bid assumed about screen failure rate, visit duration and query volume, because those are where the variance is.

Agree the change order process and a threshold above which approval is required before work proceeds. Without one, the first surprise arrives as an invoice.

Common questions

What do clinical trial support services usually cover?
Monitoring, data management, central laboratory analysis, investigational product supply, biostatistics, medical writing and regulatory submission support. They are frequently bought as a bundle and are distinct markets with distinct specialists.
Does outsourcing transfer responsibility?
No. The sponsor retains regulatory responsibility for trial conduct however much is delegated, which is why a documented oversight plan is expected and why delegation has to be recorded rather than assumed.
Should everything go to one provider?
A single provider reduces coordination and gives you one relationship to manage and one point of failure. Splitting functions gets specialists and costs integration effort. Study size and internal capacity usually decide which is right.
What is the most commonly missed contract term?
What comes back at the end: the data in an analysable form, the trial master file, the site contacts and the right to approach them. Close-out is negotiated at the start or it is not negotiated at all.

Get a shortlist for your project

Free. We send a shortlist of vendors whose published prices and service scope fit what you described, built from the verified index on this site. We may email you about this enquiry and similar services from this site; opt out any time, including from the first message.

Browse by service class

Sources

Cite or embed this figure

The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.

Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/clinical-trial-support-services/.

Embed this figure (plain HTML, no scripts)
median advertised gene synthesis price per base pair · the US research synthesis services market · August 2026

$0.11

Middle 50%$0.07 – $0.15
verified vendor service pages4

Source: BioBricks Synthesis Price Index

Get a vendor shortlistCompare synthesis prices